Market capitalization | $4.10m |
Enterprise Value | $3.45m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.42 |
P/S ratio (TTM) P/S ratio | 0.50 |
P/B ratio (TTM) P/B ratio | 2.73 |
Revenue growth (TTM) Revenue growth | -16.55% |
Revenue (TTM) Revenue | $8.18m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast ReShape Lifesciences, Inc.:
1 Analyst has issued a forecast ReShape Lifesciences, Inc.:
Sep '24 |
+/-
%
|
||
Revenue | 8.18 8.18 |
17%
17%
|
|
Gross Profit | 5.58 5.58 |
5%
5%
|
|
EBITDA | -7.90 -7.90 |
53%
53%
|
EBIT (Operating Income) EBIT | -7.92 -7.92 |
55%
55%
|
Net Profit | -7.07 -7.07 |
73%
73%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ReShape Lifesciences Inc. operates as a medical device company, which focuses on technology to treat obesity and metabolic diseases. It operates through the following segments: Lap-Band, ReShape Vest and ReShape vBloc. The company was founded on December 2002 and is headquartered in San Clemente, CA.
Head office | United States |
CEO | Paul Hickey |
Employees | 31 |
Founded | 2002 |
Website | www.reshapelifesciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.